首頁 › 頭頸部鱗狀細胞癌 › 明尼蘇達 › Minneapolis
Minneapolis, MN 的 頭頸部鱗狀細胞癌 臨床試驗
9 項針對 頭頸部鱗狀細胞癌 的研究正在 Minneapolis（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
招募中3 期
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 距離 5 英里
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
招募中2 期
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 距離 5 英里
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- Minnesota Oncology and Hematology PA, Minneapolis
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
招募中2 期
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- 還有 1 項
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
招募中1 期
- University of Minnesota Masonic Cancer Center, Minneapolis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Minneapolis
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
招募中1/2 期
- M Health Fairview University of Minnesota Medical Center, Minneapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200, Minneapolis
其他城市的 頭頸部鱗狀細胞癌 試驗
- Houston, TX47 項研究
- Los Angeles, CA42 項研究
- Boston, MA40 項研究
- Nashville, TN39 項研究
- New York City, NY39 項研究
- St. Louis, MO28 項研究
- Arlington, VA26 項研究
- Chicago, IL26 項研究
- Philadelphia, PA26 項研究
- Atlanta, GA24 項研究
- San Antonio, TX22 項研究
- Pittsburgh, PA22 項研究
Minneapolis 的其他研究
- 非小細胞肺癌27 項研究
- 乳癌27 項研究
- 卵巢癌24 項研究
- 前列腺癌23 項研究
- 癌症（所有類型）22 項研究
- 心臟衰竭21 項研究
- 急性髓系白血病20 項研究
- 肺癌20 項研究
- 大腸直腸癌19 項研究
- 子宮內膜癌18 項研究
- 帕金森氏症17 項研究
- 心血管疾病15 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。